Biote Corp. Reports Mixed Q4 Results; Revenue Misses, EPS Beats, Shares Dip
Biote Corp. (NASDAQ:BTMD), a provider of hormone optimization therapies and wellness solutions, announced its financial results for the fourth quarter and full year ended December 31, 2025. The report presented a mixed picture, with earnings per share surpassing analyst expectations but revenue falling short. The market's immediate reaction was negative, with shares trading lower following the announcement.
Earnings and Revenue Versus Estimates
The company's performance against Wall Street's projections forms the core of the quarterly narrative. Biote's results showed a clear divergence between its top and bottom-line figures relative to expectations.
- Revenue: For the fourth quarter, Biote reported total revenue of $46.4 million. This represents a 6.9% decline from the $49.8 million reported in the prior-year period and came in below the analyst consensus estimate of approximately $47.1 million.
- Earnings Per Share (EPS): On a non-GAAP basis, diluted EPS attributable to Biote Corp. stockholders was $0.06 for the quarter. This figure exceeded the analyst estimate of $0.051, providing a positive note on profitability despite the sales shortfall.
The discrepancy highlights the impact of the company's ongoing operational restructuring. While sales were pressured, significant reductions in operating expenses—primarily due to a temporary decrease in headcount from a sales reorganization—helped bolster the bottom-line result.
Market Reaction and Price Action
The market's response to the mixed report was decisively negative in after-hours trading. Following the earnings release, Biote's stock price declined, reflecting investor concern over the revenue miss and the company's cautious near-term outlook. This price action suggests that, in this instance, the market prioritized the top-line weakness and forward guidance over the earnings beat.
Key Elements from the Press Release
Beyond the headline numbers, management commentary and forward guidance provided critical context for the results and the stock's reaction.
- Commercial Transition Impact: CEO Bret Christensen acknowledged that 2025 was a transition year, with a reorganization of the commercial sales team impacting financial performance as expected. He stated the company is now "more agile and more disciplined" but noted work remains to optimize performance.
- Diverging Business Segments: The financials revealed a stark contrast between the company's two main revenue streams. Procedure revenue, which is tied to hormone pellet therapies, declined by 13.0% in Q4 to $31.8 million. This was partially offset by a 16.0% growth in dietary supplements revenue, which reached $11.7 million. For the full year, procedure revenue fell 8.8% while supplement revenue grew 19.1%.
- 2026 Financial Outlook: Management provided specific guidance for the current year, which appears to be a primary driver of investor sentiment. The company expects:
- Full-Year 2026 Revenue: Above $190 million.
- Full-Year 2026 Adjusted EBITDA: Above $38 million.
- Near-Term Headwinds: Procedure revenue is projected to decrease at a "mid to high single digit" rate year-over-year in the first half of 2026, with a return to growth anticipated in the second half. Dietary supplement revenue is expected to grow at a mid-to-high single-digit rate.
This outlook, particularly the forecast for a decline in core procedure revenue through mid-2026, underscores the ongoing challenges of the sales force rebuild. The company plans to continue investing heavily in sales and technology capabilities throughout the year, which will increase operating expenses but is deemed essential for long-term growth.
Comparison to Analyst Estimates
The company's revenue outlook for 2026, stated as "above $190 million," aligns cautiously with the current analyst consensus sales estimate of approximately $200.1 million for the full year. However, the projected path to that figure, involving a first-half decline, may have tempered investor enthusiasm. The significant planned investments also imply that near-term profitability metrics like Adjusted EBITDA, guided to be above $38 million versus $53.5 million in 2025, will face pressure.
Conclusion
Biote Corp.'s fourth-quarter earnings report paints a picture of a company in the midst of a strategic pivot. While cost discipline enabled an earnings beat, the core procedure business continues to contract as the company rebuilds its commercial foundation. The market's negative reaction reflects concerns over the timeline for a return to sustainable growth and the near-term financial cost of the company's investment plans. The success of Biote's strategy now hinges on its ability to execute its sales expansion and realize the anticipated return to procedure growth in the latter half of 2026.
For a detailed look at Biote's historical earnings and future analyst projections, you can review the company's earnings history and forecast estimates.
Disclaimer: This article is for informational purposes only and does not constitute financial advice, nor a recommendation to buy or sell any security. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions.